Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Assets Average (2021 - 2025)

Historic Assets Average for Xeris Biopharma Holdings (XERS) over the last 5 years, with Q3 2025 value amounting to $352.4 million.

  • Xeris Biopharma Holdings' Assets Average rose 797.14% to $352.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $352.4 million, marking a year-over-year increase of 797.14%. This contributed to the annual value of $322.8 million for FY2024, which is 321.71% down from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Assets Average stood at $352.4 million, which was up 797.14% from $325.1 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Assets Average ranged from a high of $352.4 million in Q3 2025 and a low of $217.8 million during Q4 2021
  • Over the past 5 years, Xeris Biopharma Holdings' median Assets Average value was $325.1 million (recorded in 2023), while the average stood at $320.1 million.
  • In the last 5 years, Xeris Biopharma Holdings' Assets Average skyrocketed by 4864.73% in 2022 and then crashed by 314.08% in 2025.
  • Xeris Biopharma Holdings' Assets Average (Quarter) stood at $217.8 million in 2021, then surged by 48.65% to $323.8 million in 2022, then rose by 0.44% to $325.2 million in 2023, then dropped by 0.96% to $322.1 million in 2024, then rose by 9.43% to $352.4 million in 2025.
  • Its Assets Average stands at $352.4 million for Q3 2025, versus $325.1 million for Q2 2025 and $319.3 million for Q1 2025.